CRONOS GROUP INC (CRON) Fundamental Analysis & Valuation

NASDAQ:CRON • CA22717L1013

2.57 USD
0 (0%)
At close: Mar 6, 2026
2.56 USD
-0.01 (-0.39%)
After Hours: 3/6/2026, 8:09:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

CRON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. CRON Profitability Analysis

1.1 Basic Checks

  • In the past year CRON has reported negative net income.
  • CRON had a positive operating cash flow in the past year.
  • CRON had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CRON reported negative operating cash flow in multiple years.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • CRON has a Return On Assets of -0.79%. This is in the better half of the industry: CRON outperforms 77.72% of its industry peers.
  • CRON's Return On Equity of -0.86% is amongst the best of the industry. CRON outperforms 80.31% of its industry peers.
Industry RankSector Rank
ROA -0.79%
ROE -0.86%
ROIC N/A
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

1.3 Margins

  • The Gross Margin of CRON (42.81%) is better than 63.21% of its industry peers.
  • CRON's Gross Margin has improved in the last couple of years.
  • CRON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K 4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. CRON Health Analysis

2.1 Basic Checks

  • CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRON has less shares outstanding than it did 1 year ago.
  • CRON has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 7.17 indicates that CRON is not in any danger for bankruptcy at the moment.
  • CRON has a better Altman-Z score (7.17) than 80.83% of its industry peers.
  • There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.17
ROIC/WACCN/A
WACC8.59%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 19.59 indicates that CRON has no problem at all paying its short term obligations.
  • CRON has a Current ratio of 19.59. This is amongst the best in the industry. CRON outperforms 89.64% of its industry peers.
  • A Quick Ratio of 18.62 indicates that CRON has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 18.62, CRON belongs to the best of the industry, outperforming 89.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.59
Quick Ratio 18.62
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CRON Growth Analysis

3.1 Past

  • The earnings per share for CRON have decreased strongly by -104.00% in the last year.
  • CRON shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.63%.
  • Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 25.70% on average per year.
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%

3.2 Future

  • Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -72.39% on average per year.
  • CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.19% yearly.
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue Next Year37.98%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. CRON Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Forward Earnings ratio is 39.79, which means the current valuation is very expensive for CRON.
  • 70.98% of the companies in the same industry are more expensive than CRON, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (24.57), we can say CRON is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 39.79
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CRON's earnings are expected to grow with 210.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y359.62%
EPS Next 3Y210.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRON Dividend Analysis

5.1 Amount

  • No dividends for CRON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRON Fundamentals: All Metrics, Ratios and Statistics

CRONOS GROUP INC

NASDAQ:CRON (3/6/2026, 8:09:49 PM)

After market: 2.56 -0.01 (-0.39%)

2.57

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners15.01%
Inst Owner Change2.5%
Ins Owners6.28%
Ins Owner Change0.47%
Market Cap974.16M
Revenue(TTM)146.59M
Net Income(TTM)-9.45M
Analysts82.22
Price Target3.44 (33.85%)
Short Float %1.8%
Short Ratio2.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.13%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)12.75%
Revenue beat(4)1
Avg Revenue beat(4)1.94%
Min Revenue beat(4)-4.49%
Max Revenue beat(4)12.75%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.47%
Revenue beat(16)6
Avg Revenue beat(16)-2.81%
PT rev (1m)-6.62%
PT rev (3m)-5.01%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.07%
Revenue NQ rev (3m)-12.01%
Revenue NY rev (1m)1%
Revenue NY rev (3m)-0.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.79
P/S 6.65
P/FCF N/A
P/OCF 37.66
P/B 0.89
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.06
Fwd EY2.51%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.07
OCFY2.66%
SpS0.39
BVpS2.89
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.79%
ROE -0.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.81%
FCFM N/A
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
F-Score7
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 183.09%
Cap/Sales 17.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.59
Quick Ratio 18.62
Altman-Z 7.17
F-Score7
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)118.29%
Cap/Depr(5y)94.57%
Cap/Sales(3y)10.61%
Cap/Sales(5y)10.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
Revenue Next Year37.98%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
EBIT growth 1Y75.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.41%
EBIT Next 3Y74.89%
EBIT Next 5Y-8.2%
FCF growth 1Y-103.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.27%
OCF growth 3YN/A
OCF growth 5YN/A

CRONOS GROUP INC / CRON FAQ

What is the fundamental rating for CRON stock?

ChartMill assigns a fundamental rating of 5 / 10 to CRON.


What is the valuation status of CRONOS GROUP INC (CRON) stock?

ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.


What is the profitability of CRON stock?

CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.